Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients.
A decreased incidence of cancer of the prostate has been demonstrated in a cohort of 6168 chronic schizophrenic patients followed up from 1957 to 1984. A case-control study was performed based on this cohort to determine the possible influence of neuroleptic treatment and other factors on the risk of developing prostate cancer. Thirty-eight male schizophrenic patients who had developed prostate cancer during the observation period were compared with 76 age- and sex-matched controls from the same cohort. The only significant association was that of a reduced risk of prostate cancer among those who had been treated with a cumulative dose of high-dose phenothiazines (primarily chlorpromazine) of 15 g or more. These patients had been treated with an average daily dose of 145 mg chlorpromazine for an average of 12.5 years. No other significant risk factors were identified.
Institute of Psychiatric Demography, Aarhus Psychiatric Hospital, Risskov, Denmark.
P B
PB
Mortensen
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002746:Chlorpromazine / Q000627:therapeutic use; D002908:Chronic Disease; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D003718:Denmark / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015994:Incidence; D008019:Life Style; D008297:Male; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000517:prevention & control* / Q000523:psychology; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology; D012565:Schizophrenic Psychology; D012803:Sick Role
D014150:Antipsychotic Agents; D002746:Chlorpromazine